Louis Letendre

2.9k total citations
76 papers, 2.1k citations indexed

About

Louis Letendre is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Louis Letendre has authored 76 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Hematology, 24 papers in Genetics and 20 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Louis Letendre's work include Acute Myeloid Leukemia Research (34 papers), Acute Lymphoblastic Leukemia research (19 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Louis Letendre is often cited by papers focused on Acute Myeloid Leukemia Research (34 papers), Acute Lymphoblastic Leukemia research (19 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Louis Letendre collaborates with scholars based in United States, Taiwan and United Kingdom. Louis Letendre's co-authors include Ayalew Tefferi, Shaji Kumar, H. Clark Hoagland, Alexandra P. Wolanskyj, Mark R. Litzow, Sameer A. Parikh, Prashant Kapoor, Joseph M. Kiely, Rajiv K. Pruthi and Gordon W. Dewald and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Louis Letendre

72 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Louis Letendre United States 25 1.1k 563 490 399 338 76 2.1k
Charles Linker United States 23 944 0.9× 657 1.2× 337 0.7× 339 0.8× 191 0.6× 58 2.1k
Gunnar Öberg Sweden 27 1.3k 1.2× 453 0.8× 484 1.0× 313 0.8× 319 0.9× 59 2.1k
Adrian Goycoolea 2 1.6k 1.5× 796 1.4× 424 0.9× 556 1.4× 281 0.8× 3 2.8k
Gwynn D. Long United States 23 1.2k 1.1× 759 1.3× 403 0.8× 542 1.4× 190 0.6× 83 2.0k
Diane Coso France 25 929 0.9× 582 1.0× 318 0.6× 309 0.8× 212 0.6× 78 1.7k
Claire Galambrun France 29 1.3k 1.2× 395 0.7× 483 1.0× 494 1.2× 312 0.9× 79 2.5k
Donna L. Forrest Canada 27 1.4k 1.3× 482 0.9× 737 1.5× 265 0.7× 422 1.2× 110 2.3k
F R Appelbaum United States 25 2.2k 2.0× 876 1.6× 479 1.0× 655 1.6× 340 1.0× 47 3.0k
Prakash Satwani United States 28 1.0k 0.9× 550 1.0× 453 0.9× 474 1.2× 271 0.8× 138 2.1k
Görgün Akpek United States 25 1.1k 1.0× 465 0.8× 399 0.8× 385 1.0× 403 1.2× 65 2.0k

Countries citing papers authored by Louis Letendre

Since Specialization
Citations

This map shows the geographic impact of Louis Letendre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louis Letendre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louis Letendre more than expected).

Fields of papers citing papers by Louis Letendre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Louis Letendre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louis Letendre. The network helps show where Louis Letendre may publish in the future.

Co-authorship network of co-authors of Louis Letendre

This figure shows the co-authorship network connecting the top 25 collaborators of Louis Letendre. A scholar is included among the top collaborators of Louis Letendre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Louis Letendre. Louis Letendre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barreto, Jason N., Kristen McCullough, Ross Dierkhising, et al.. (2017). Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. Leukemia & lymphoma. 58(11). 2588–2597. 11 indexed citations
2.
Gangat, Naseema, Mrinal M. Patnaik, Kebede H. Begna, et al.. (2015). Primary Myelodysplastic Syndromes. Mayo Clinic Proceedings. 90(12). 1623–1638. 14 indexed citations
3.
Parikh, Sameer A., Prashant Kapoor, Louis Letendre, Shaji Kumar, & Alexandra P. Wolanskyj. (2014). Prognostic Factors and Outcomes of Adults With Hemophagocytic Lymphohistiocytosis. Mayo Clinic Proceedings. 89(4). 484–492. 222 indexed citations
4.
Elliott, Michelle A., Louis Letendre, Ayalew Tefferi, et al.. (2011). Therapy‐related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy*. European Journal Of Haematology. 88(3). 237–243. 17 indexed citations
5.
Elliott, Michelle A., Robert Christian Wolf, C. Christopher Hook, et al.. (2004). Thromboembolism in Adults with Acute Lymphoblastic Leukemia During Induction with L-Asparaginase-containing Multi-agent Regimens: Incidence, Risk Factors, and Possible Role of Antithrombin. Leukemia & lymphoma. 45(8). 1545–1551. 45 indexed citations
6.
Elliott, Michelle A., Louis Letendre, Curtis A. Hanson, Ayalew Tefferi, & Gordon W. Dewald. (2002). The Prognostic Significance of Trisomy 8 in Patients With Acute Myeloid Leukemia. Leukemia & lymphoma. 43(3). 583–586. 11 indexed citations
7.
Hogan, William J., Louis Letendre, Mark R. Litzow, et al.. (2002). Neutropenic Colitis After Treatment of Acute Myelogenous Leukemia With Idarubicin and Cytosine Arabinoside. Mayo Clinic Proceedings. 77(8). 760–762. 28 indexed citations
8.
Tefferi, Ayalew, David P. Steensma, C. Christopher Hook, et al.. (2001). Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leukemia Research. 25(2). 183–185. 15 indexed citations
9.
Steensma, David P., Curtis A. Hanson, Louis Letendre, & Ayalew Tefferi. (2001). Myelodysplasia with fibrosis: a distinct entity?. Leukemia Research. 25(10). 829–838. 38 indexed citations
10.
Kim, Kyung‐Min, MM Oken, Louis Letendre, et al.. (2000). Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483). Leukemia. 14(8). 1349–1353. 25 indexed citations
11.
Elliott, Michelle A., Louis Letendre, A Tefferi, Curtis A. Hanson, & Gordon W. Dewald. (2000). Trisomy 8 in acute myeloid leukemia. 1. 70816.
12.
Vliet, Hans van, et al.. (2000). All‐trans‐retinoic acid‐induced myositis: A description of two patients. American Journal of Hematology. 63(2). 94–98. 1 indexed citations
13.
Elliott, Michelle A., Louis Letendre, Chin‐Yang Li, James D. Hoyer, & Julie E. Hammack. (1999). Chronic lymphocytic leukaemia with symptomatic diffuse central nervous system infiltration responding to therapy with systemic fludarabine. British Journal of Haematology. 104(4). 689–694. 24 indexed citations
14.
Letendre, Louis, et al.. (1997). Successful pregnancy after conditioning with cyclophosphamide and fractionated total body irradiation. Medical and Pediatric Oncology. 28(2). 147–148. 6 indexed citations
15.
Kaufmann, Scott H., Steven D. Gore, Louis Letendre, et al.. (1996). Factors Affecting Topotecan Sensitivity in Human Leukemia Samplesa. Annals of the New York Academy of Sciences. 803(1). 128–142. 9 indexed citations
16.
Afessa, Bekele, Ayalew Tefferi, H. Clark Hoagland, Louis Letendre, & Steve G. Peters. (1992). Outcome of Recipients of Bone Marrow Transplants Who Require Intensive-Care Unit Support. Mayo Clinic Proceedings. 67(2). 117–122. 134 indexed citations
17.
Lust, John A., Louis Letendre, & Stephen N. Thibodeau. (1989). Marrow hypoplasia associated with a monoclonal CD8 large granular lymphocyte proliferation: reversal with cyclophosphamide and prednisone☆. The American Journal of Medicine. 87. 214–217. 2 indexed citations
18.
Mailliard, James A., Louis Letendre, Robert J. Dalton, et al.. (1986). Phase I–II trial of VP‐16 in the treatment of acute nonlymphocytic leukemia and blast crisis of chronic granulocytic leukemia. Medical and Pediatric Oncology. 14(6). 306–309. 5 indexed citations
19.
Letendre, Louis, et al.. (1985). Phase I study of VP‐16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. Medical and Pediatric Oncology. 13(4). 232–234. 17 indexed citations
20.
Letendre, Louis & Robert A. Kyle. (1982). Monoclonal Cryoglobulinemia With High Thermal Insolubility. Mayo Clinic Proceedings. 57(10). 629–633. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charles Linker Breakdown of academic impact, for papers by Gunnar Öberg Breakdown of academic impact, for papers by Adrian Goycoolea Breakdown of academic impact, for papers by Gwynn D. Long Breakdown of academic impact, for papers by Diane Coso Breakdown of academic impact, for papers by Claire Galambrun Breakdown of academic impact, for papers by Donna L. Forrest Breakdown of academic impact, for papers by F R Appelbaum Breakdown of academic impact, for papers by Prakash Satwani Breakdown of academic impact, for papers by Görgün Akpek
Rankless by CCL
2026